US Biotechnology: Rescheduled: CEO Call Series: Conversation with AGIO management

Research evidence excerpt

US Biotechnology: Rescheduled: CEO Call Series: Conversation with AGIO management

Accessible version

US Biotechnology

Rescheduled: CEO Call Series: Conversation

with AGIO management

Invitation

Topic 13 July 2026 Rescheduled

We are hosting the management team from Agios Pharmaceuticals (AGIO), including Equity

Brian Goff, CEO, and Dr. Krishnan, CSO/COO, to run through key stock drivers and recent United States

updates ahead of 2Q earnings. Agios has had a wealth of recent updates (see eight Biotechnology

reports we’ve written on Agios in the past few months linked in this invitation). Our

Related Researchconversation with Agios management will focus on: 1) expectations heading into 2Q

US Biotechnology: 2Q26 Earnings Preview:

earnings in thalassemia and pyruvate-kinase deficiency (PKD), 2) regulatory outlook for MRNA, TGTX, CRSP, AGIO, NVAX, & HCM 07

sickle cell disease (SCD) and EU labeling/expansion, 3) recent data updates at the July 2026

European Hematology Association (EHA) congress and setup into 2H26 data catalysts Agios Pharmaceuticals: EHA update

(tebapivat in SCD, etc.), and 4) early stage programs including newly acquired CYK strengthens SCD path ahead of imminent

sNDA acceptance

inhibitor Cevidoplenib. The conversation will be contextualized within the broader Agios Pharmaceuticals: Takeaways from our

hematology landscape, key debates about commercial opportunity/viability, and where thalassemia expert call on AQVESME launch

the next legs of growth could come from within the pipeline. outlook

Agios Pharmaceuticals: Thalassemia

Host Speaker(s) Date and Time prescriber survey bullish on AQVESME launch, limited REMS impact

Alec Stranahan, US SMid-cap Tuesday, July 21, 2026 11:00 AM Eastern Time Agios Pharmaceuticals: Tebapivat LR-MDS